Organoids Will Replace Most Animal Studies Within 10 Years—But Only If We Fix the System Problem

The median human clinical trial fails. Animal models predict human efficacy about 50% of the time. The problem isn't just species differences—it's that animals are complete organisms and our targets are often tissue-specific.
Organoids change the equation: human genetic fidelity, disease-specific mutations, and scalability. But here's the catch—they lack systemic context. The question isn't whether organoids can replace animals. It's which experimental questions require systemic factors, and how we add them back in.
My hypothesis: within a decade, 70%+ of preclinical efficacy studies will use organoid-first designs. The deep dive explains which biology this works for, what fails, and how to engineer the missing pieces.